OncoMatch/Clinical Trials/NCT07285044
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Is NCT07285044 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Cancer Therapeutic Procedure for amyloidosis.
Treatment: Cancer Therapeutic Procedure — This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Urothelial Carcinoma
Breast Carcinoma
Cervical Cancer
Colorectal Cancer
Endometrial Cancer
Ovarian Cancer
Gastric Cancer
Esophageal Carcinoma
Glioblastoma
Head and Neck Squamous Cell Carcinoma
Hepatocellular Carcinoma
Hodgkin Lymphoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Non-Hodgkin Lymphoma
Melanoma
Multiple Myeloma
Myelodysplastic Syndrome
Pancreatic Cancer
Prostate Cancer
Renal Cell Carcinoma
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: standard-of-care therapy (Atezolizumab, Bevacizumab, Avelumab, Bortezomib, Cemiplimab, Daratumumab, Darbepoetin alpha, Degarelix, Denosumab, Durvalumab, Fluorouracil, Fulvestrant, Goserelin, Ipilimumab, Lanreotide, Leuprolide, Nivolumab, Octreotide, Pembrolizumab, Pertuzumab, Trastuzumab, Zoledronic acid, Nivolumab + relatlimab, Ipilimumab + Nivolumab, Daratumumab + bortezomib, Atezolizumab + bevacizumab, Fluorouracil + bevacizumab, Pertuzumab + trastuzumab, Trastuzumab + pertuzumab) — disease-specific standard of care
Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. NCCN, ASCO, ASH, etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines
Cannot have received: investigational agent
Receiving any investigational agent which would be considered as a treatment for the primary neoplasm
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Florida · Jacksonville, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07285044 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages